Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 8/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.56 |
| ▸ | ACHE | P22303 | 3/20 | 0.50 |
| ▸ | OGA | O60502 | 1/20 | 0.49 |
| ▸ | HTR3A | P46098 | 2/20 | 0.49 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | CDK9 | P50750 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29958994 | 1.00 | HRH4 (0.56) | HRH4HRH3ACHEOGAHTR3A | |
| SCHEMBL10187275 | 0.83 | KDM1A (0.48) | HRH4ACHEOGACCNT1CCNA2 | |
| SCHEMBL4947574 | 0.83 | KDM1A (0.48) | HRH4ACHEOGACCNT1CCNA2 | |
| SCHEMBL5458689 | 0.82 | ACHE (0.56) | HRH3ACHEOGA | |
| SCHEMBL9900073 | 0.81 | KDM1A (0.47) | HRH4ACHEOGACCNT1CCNA2 | |
| SCHEMBL9488628 | 0.80 | SORD (0.56) | HRH4HRH3ACHEOGAHTR3A | |
| SCHEMBL11113279 | 0.80 | ACHE (0.51) | HRH4HRH3ACHEHTR3ACCNT1 | |
| SCHEMBL24827231 | 0.79 | ACHE (0.52) | HRH3ACHEOGA | |
| SCHEMBL31457533 | 0.79 | ACHE (0.52) | HRH4HRH3ACHEOGACDK2 | |
| SCHEMBL6800518 | 0.79 | ACHE (0.55) | ACHEOGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289801-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2025-09-18 | — | — | US | disclosed |
| EP-4534532-A1 | HETEROARYL DERIVATIVE COMPOUND AND USES THEREOF | Voronoi Inc. (KR) | 2025-04-09 | — | — | EP | disclosed |
| US-12172983-B2 | EGFR inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2024-12-24 | — | — | US | disclosed |
| US-11718602-B2 | EGFR inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718602-B2 | EGFR inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718602-B2 | EGFR inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230056541-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-02-23 | — | — | US | disclosed |
| US-20230056541-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-02-23 | — | — | US | disclosed |
| US-20230026209-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-01-26 | — | — | US | disclosed |
| US-20230026209-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-01-26 | — | — | US | disclosed |
| CN-115135642-A | Inhibitors of mutant forms of EGFR | 缆图药品公司 | 2022-09-30 | — | — | CN | disclosed |
| WO-2021133809-A1 | INHIBITORS OF MUTANT FORMS OF EGFR | BLUEPRINT MEDICINES CORPORATION (US) | 2021-07-01 | — | — | WO | disclosed |
| US-8901119-B2 | Peptide deformylase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2014-12-02 | — | — | US | disclosed |
| EP-2684039-A2 | PEPTIDE DEFORMYLASE INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2014-01-15 | — | — | EP | disclosed |
| US-20130345120-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-12-26 | — | — | US | disclosed |
| WO-2012122450-A2 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-09-13 | — | — | WO | disclosed |
| WO-2008089034-A2 | CYTOKINE INHIBITORS | KEMIA, INC. (US) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230056541-A1 | EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | HRH4 3956/4885HRH3 4103/4885ACHE 4885/4885 |
| US-20230026209-A1 | EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | HRH4 3956/4885HRH3 4103/4885ACHE 4885/4885 |
| US-11718602-B2 | EGFR inhibitors | EGFR, ERBB2, ERBB3 | HRH4 3956/4885HRH3 4103/4885ACHE 4885/4885 |
| US-12172983-B2 | EGFR inhibitors | EGFR, ERBB2, ERBB3 | HRH4 3956/4885HRH3 4103/4885ACHE 4885/4885 |
| US-20250289801-A1 | EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | HRH4 3956/4885HRH3 4103/4885ACHE 4885/4885 |
| US-20130345120-A1 | PEPTIDE DEFORMYLASE INHIBITORS | PDF, PEPD, VIP | HRH4 2308/4885HRH3 2507/4885ACHE 4770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.